Related Experiment Video
Updated: Jun 27, 2026
Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs
Published on: December 27, 2016
[Effect of mitogen-activated protein kinases on ATRA-induced differentiation of NB4 cells]
Su Wang1, Yun-Peng Liu, Ke-Zuo Hou
1Department of Oncology, The First Hospital, China Medical University, Shenyang 110001, Liaoning Province, China.
Abstract:
The aim of this study was to observe the effect of p38MAPK inhibitor SB203580 on ATRA-induced differentiation of NB4 cells. The proliferation activity of cells was assayed by MTT method, the cell cycle was detected by flow cytometry, the differentiation of NB4 cells into granulocytes was measured by test of NBT reduction, the activity of extracellular signal-regulated kinase (ERK) was detected by substrate phosphorylation. The results showed that the ATRA in 0.01-01 micromol/L inhibited the proliferation of NB4 cells in time-and dose-dependent manner and induced the differentiation of NB4 cells into myeloid; the ATRA stimulated ERK activity in this process; ERK inhibitor PD98059 could partially block ATRA effect, specific inhibitor of p38MAPK, SB203580, combined with ATRA also could partially block the effects of ATRA on inhibition of NB4 growth and induction of differentiation. It is concluded that the ATRA stimulates ERK and p38MAPK pathway in the process inducing differentiation of NB4 cells, the ERK and P38MAPK may be necessary for the ATRA-induced differentiation in NB4 cells.
Insights
All-trans retinoic acid (ATRA) induces differentiation of NB4 cells into myeloid cells by stimulating extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) pathways. These pathways are crucial for ATRA
Area of Science:
- Cell Biology
- Molecular Biology
- Pharmacology
Background:
- All-trans retinoic acid (ATRA) is a key therapeutic agent used in treating acute promyelocytic leukemia (APL).
- Understanding the molecular mechanisms underlying ATRA-induced cellular differentiation is crucial for optimizing APL treatment strategies.
- NB4 cells are a human promyelocytic leukemia cell line commonly used to study ATRA-induced differentiation.
Purpose of the Study:
- To investigate the role of p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 in all-trans retinoic acid (ATRA)-induced differentiation of NB4 cells.
- To elucidate the involvement of extracellular signal-regulated kinase (ERK) and p38MAPK signaling pathways in ATRA-mediated cellular responses.
Main Methods:
- Cell proliferation was assessed using the MTT assay.
- Cell cycle analysis was performed via flow cytometry.
- Granulocytic differentiation was quantified by NBT reduction assay.
- Extracellular signal-regulated kinase (ERK) activity was measured by substrate phosphorylation.
Main Results:
- ATRA inhibited NB4 cell proliferation and induced myeloid differentiation in a time- and dose-dependent manner.
- ATRA treatment stimulated ERK activity, and its effects were partially blocked by the ERK inhibitor PD98059.
- The p38MAPK inhibitor SB203580, when combined with ATRA, partially inhibited ATRA's effects on NB4 cell growth and differentiation.
Conclusions:
- All-trans retinoic acid (ATRA) activates both ERK and p38MAPK signaling pathways during NB4 cell differentiation.
- ERK and p38MAPK signaling pathways appear to be essential for ATRA-induced differentiation of NB4 cells.
- Targeting these pathways may offer novel therapeutic strategies for enhancing ATRA efficacy in APL treatment.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:07MAPK Signaling Cascades